Node positivity in T1b gallbladder cancer: A high volume centre experience

Goel, Mahesh; Pandrowala, Saneya; Patel, Prerak; Patkar, Shraddha

doi:10.1016/j.ejso.2022.03.013

Cited by 9 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there has been an argument over the treatment of T1b GBC. According to previous studies, lymph node metastasis occurred in 15%-21% of T1b GBC patients, which was much higher than that in T1a patients (Ogura et al, 1991;Vo et al, 2019;Goel et al, 2022). The postoperative recurrence rate of T1b GBC patients was significantly higher than that of T1a GBC patients (9% vs. 1%, p < 0.01).…”

Section: Tis/t1 Stagementioning

confidence: 82%

“…Vo et al (2019) analyzed T1b GBC patients in the National Cancer Data Base from 2004 to 2012, and found that the 5-year overall survival (OS) rate would be reduced from 64.4% to 48.3% if the patients only received simple resection. Hence, it is highly recommended to perform the same radical operation as T2, especially regional lymphadenectomy, for T1b GBC patients (Fetzner et al, 2011;Vo et al, 2019;Goel et al, 2022). Xu et al (2020) conducted specific research on the optimal number of regional lymph nodes that should be dissected and found that patients undergoing simple resection and lymphadenectomy (>5 lymph nodes) had a higher overall survival (OS) rate than those not undergoing regional lymphadenectomy.…”

Section: Tis/t1 Stagementioning

confidence: 99%

“…Xu et al (2020) conducted specific research on the optimal number of regional lymph nodes that should be dissected and found that patients undergoing simple resection and lymphadenectomy (>5 lymph nodes) had a higher overall survival (OS) rate than those not undergoing regional lymphadenectomy. GBC exhibits a high degree of malignancy and a high rate of lymph node metastasis; regional lymphadenectomy is accompanied by a low incidence of complications and a low mortality rate, and determining the status of lymph node metastasis contributes to the formulation of postoperative adjuvant therapy for patients (Goel et al, 2022). Therefore, it is suggested that T1b GBC patients…”

Section: Tis/t1 Stagementioning

confidence: 99%

See 2 more Smart Citations

Gallbladder cancer: current and future treatment options

et al. 2023

View full text Add to dashboard Cite

Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.

show abstract

Section: Tis/t1 Stagementioning

confidence: 82%

Section: Tis/t1 Stagementioning

confidence: 99%

Section: Tis/t1 Stagementioning

confidence: 99%

See 1 more Smart Citation

Gallbladder cancer: current and future treatment options

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For patients with T1b, the value of lymph node dissection still needs to be explored (91). In a nationwide retrospective cohort of GBC in Korea, Lee et al found that in patients with T1b GBC, radical surgery for GBC did not provide a significantly better prognosis than cholecystectomy alone (92), and the Korean Hepatobiliary and Pancreatic Society also had reservations about radical surgery for T1b in their guidelines (93).…”

Section: Prognosis Of Gbc Treatmentmentioning

confidence: 99%

“…For patients with T1b, the value of lymph node dissection still needs to be explored ( 91 ). In a nationwide retrospective cohort of GBC in Korea, Lee et al.…”

Section: Prognosis Of Gbc Treatmentmentioning

confidence: 99%

Progress in gallbladder cancer with lymph node metastasis

Song

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is a malignant tumor that originates from the mucosal lining of the gallbladder. It is distinctly regional and is common in certain geographic regions of developing countries. GBC has a high degree of insidiousness as well as a high propensity for metastatic spread, resulting in the majority of patients being diagnosed at an advanced stage. Lymph node metastasis (LNM) is fairly common in GBC patients and is an independent risk factor for a poor prognosis. This article is focused on the lymph node pathways and metastatic directions of GBC. Furthermore, it summarizes the different lymph node groupings, disease stages and treatments. In the future, it is of great significance to develop individualized treatment and predict the outcomes of GBC patients with different lymph node conditions.

show abstract

A Systematic Review and Meta‐Analysis of Oncologic Liver Resections in Low‐ and Middle‐Income Countries: Opportunities to Improve Evidence and Outcomes

Khan,

Mahmud,

Fatimi

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

BackgroundPatients in low‐ and middle‐income countries (LMICs) are disproportionately affected by liver cancers but there is a lack of understanding of their postoperative outcomes. This study aimed to review the current status of research in LMICs regarding outcomes after oncologic hepatectomy and synthesize the data reported in the literature.MethodsThe PubMed, Scopus, Embase, Web of Science, and World Health Organization (WHO) Global Index Medicus databases were searched from database inception to May 26th, 2022. Studies that reported outcomes after oncologic hepatectomy in LMIC settings were eligible for inclusion. Two independent reviewers performed record screening and data extraction. Risk of bias assessment was performed using the National Institutes of Health Study Quality Assessment tools. Pooled results with 95% confidence intervals (95% CIs) were calculated using a random effects model.ResultsOne hundred and thirty‐five studies and 16 985 patients were included. Most studies were of a “fair” quality. Two studies described pediatric patients. Only one study was from a low‐income country and most African regions were not represented. The rates of major and minor complications were 11% and 27%, respectively, while 30‐ and 90‐day mortality rates were 2% and 3% each. Postoperative liver failure (8%), surgical site infections (6%), and bile leaks (6%) were common complications.ConclusionsThis review indicates a dearth of data from LMICs on outcomes after hepatectomy, particularly from African regions and low‐income countries.

show abstract

Node positivity in T1b gallbladder cancer: A high volume centre experience

Cited by 9 publications

References 33 publications

Gallbladder cancer: current and future treatment options

Gallbladder cancer: current and future treatment options

Progress in gallbladder cancer with lymph node metastasis

A Systematic Review and Meta‐Analysis of Oncologic Liver Resections in Low‐ and Middle‐Income Countries: Opportunities to Improve Evidence and Outcomes

Contact Info

Product

Resources

About